India pharm company Sun Pharma is set to acquire US-based drug maker Organon & Co. at a deal valued at $11.75 billion (approximately Rs 97,500 crore), the company said in the announcement.
With this acquisition,
Sun Pharma is set to become a top 25 pharma company globally as its combined revenue could reach $12.4 billion after the deal.
By acquiring Organon, Sun Pharma is looking to enter into a big biosimilars market, a highly similar version of an approved biological medicine that has no clinically meaningful difference in safety, purity, and potency.
It will also strengthen the company’s position in women’s health, with a potential for long-term growth and earnings potential.
The deal is expected to close as early as by 2027. Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks.
The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger.
For the year ended 31st December, 2025, Organon reported US$ 6.2 billion in revenue and Adjusted EBITDA of US$ 1.9 billion. Organon had debt of US$ 8.6 billion and cash balance of US$ 574 million. Organon recently closed on a divestiture of a product for which it received an upfront payment of $440 million, the net proceeds of which will further contribute to its March 31, 2026 cash balance.
